Heterocyclyldicarbamides as caspase inhibitors
CA 2443600 A1 · Owner: Mortimore, Michael · Inventors: Golec, Julian; Knegtel, Ronald; Hercend, Thierry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel classes of compounds of formula (I) which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently can be , advantageously used as agents against caspaseinterleukin-1- ("IL-1"), apoptosis-, interferon-.gamma. inducing factor- (IGIF) interferon-.gamma.- , ("IFN-.gamma."), or TNF-alpha mediated diseases including inflammatory , diseases, autoimmune diseases destructive bone disorders, proliferative disorders, infectious diseases, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 19, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 19, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 19, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.